G
out, a common form of inflammatory arthritis, is characterized by acute intermittent episodes of synovitis that cause joint swelling and pain. Approximately 8 million persons in the United States have gout (1) . It occurs when excess urate in the body crystalizes (as monosodium urate) in joint fluid, cartilage, bones, tendons, bursas, or other sites. The crystals can directly initiate an acute inflammatory attack. In some patients, acute gout attacks become progressively more frequent, protracted, and severe and may progress to a chronic inflammatory condition. In addition, some patients develop tophi, which are deposits of urate crystals at the surface of joints or in skin or cartilage.
This systematic review was proposed by the American College of Physicians (ACP) to support the development of a clinical practice guideline that would aid primary care practitioners in the management of adult patients with gout.
RESULTS
The Figure shows the search and selection process that identified 155 articles meeting the inclusion criteria. Of these, 22 evaluated dietary therapy or traditional Chinese medicine; details about the inconclusive evidence from those studies are in the evidence report (3) .
Pharmacologic Treatment for Acute Gout
We identified evidence for several pharmacologic treatments for acute gout: colchicine, NSAIDs, corticosteroids, and animal-derived corticotropin formulation (8 -35) . None of the studies assessed differences in effectiveness by patient characteristics, such as age, sex, duration of the episode, history, genetic profile, baseline serum urate level, or presence of comorbidities.
Colchicine
Although colchicine was used to treat gout in the ninth century or earlier (36) , its use has been evaluated in only 2 randomized, placebo-controlled trials (12, 14) . These trials enrolled 184 and 43 patients, respectively, who had crystal-proven gout or met the American College of Rheumatology criteria and had mean duration of symptoms of 38 hours or less. Both studies found that patients treated with colchicine had better pain relief than placebo recipients (38% vs. 16% achieved a 50% decrease in target joint pain at 24 hours, and 41% vs. 9% achieved a 50% decrease in baseline pain score at 24 hours). The earlier trial, published in 1987, used an initial colchicine dose of 1 mg followed by 0.5 mg every 2 hours until symptom relief or adverse effects occurred (14) . All of the colchicine-treated patients had gastrointestinal adverse effects by 24 hours, and 91% reported adverse effects before achieving a 50% reduction in pain intensity. The later trial compared "lowdose" (an initial dose of 1.2 mg followed by 0.6 mg 1 hour later) versus "high-dose" (an initial dose of 1.2 mg followed by 0.6 mg per hour for 6 hours) colchicine (12) . Low-dose colchicine was as effective as high-dose colchicine compared with placebo and was much better tolerated; for example, 23% versus 77% of patients receiving low-and high-dose therapy reported diarrhea, and 0% versus 19% of these patients reported severe diarrhea ( Table 1) .
NSAIDs
One low-quality, placebo-controlled trial assessed NSAIDs in patients with acute gout (30) . This small study assessed the effect of tenoxicam (40 mg once daily) in 30 patients and found that a greater proportion of those receiving tenoxicam than those receiving placebo reported at least 50% improvement at 24 hours.
Sixteen randomized trials compared one NSAID with another (8, 9, 11, 15-19, 21-23, 27-29, 31, 32) . Most studies found no statistically significant differences in outcomes between treatments, although only 3 studies enrolled more than 100 patients (9, 22, 23), meaning that most studies were small and had limited power to detect differences (Appendix Table 2 , available at www.annals.org).
Corticosteroids
No published placebo-controlled trials assessed oral corticosteroids for acute gout. Six randomized trials compared corticosteroids (3 oral, 2 intramuscular, and 1 intravenous) versus NSAIDs. These studies, which enrolled 27 (20), 60 (13) , 90 (24) , 92 (33) , 120 (10) , and 416 (34) patients, found few differences in effectiveness or adverse events between treatments. In one study of oral corticosteroids, 90 patients presenting to the Systematic Review in Support of ACP Guideline on Management of Gout REVIEW group reported adverse events (63% vs. 27%) (24) . In another study of oral corticosteroids, 120 patients who presented to family physicians with acute monoarthritis and had monosodium urate crystals on synovial fluid examination were randomly assigned to prednisolone, 35 mg/d, or naproxen, 500 mg twice daily. Over the subsequent 4 days, no statistically significant differences in effectiveness outcomes were observed between groups. Equal proportions of patients in both groups reported an adverse event (66% vs. 63%) (10) . The third study of oral corticosteroids randomly assigned 416 patients with a clinical diagnosis of gout with symptoms lasting less than 3 days to indomethacin or prednisolone for 5 days. There were no important statistically or clinically significant differences in pain outcomes or overall adverse events. Gastrointestinal adverse events were more common in the indomethacin-treated patients, and skin rash was more common in the prednisolone-treated patients (34) ( Table 1) .
Corticotropin
No published placebo-controlled trials tested corticotropin for acute gout. Two randomized, controlled trials compared intramuscular corticotropin versus other active agents. One evaluated corticotropin, 40 IU, versus triamcinolone, 60 mg, both given intramuscularly only once (26) ; the other evaluated corticotropin, 40 IU once, versus indomethacin, 50 mg 4 times a day until pain abated (25) . In the former study, patients treated with triamcinolone required fewer reinjections for inadequate pain relief than those treated with corticotropin at up to 30 days of follow-up (5 vs. 9 patients; P = 0.11). In the latter study, pain relief was faster with corticotropin than with oral indomethacin (3 vs. 24 hours to total pain relief), and at the dose of 50 mg 4 times a day, 55% of indomethacin-treated patients reported gastrointestinal adverse events (no adverse events were reported by patients receiving corticotropin) ( Table 1) .
Summary
Despite the small number of placebo-controlled trials, we judged the strength of evidence as high that colchicine, NSAIDs, and corticosteroids relieve pain in patients with acute gout, based on the known physiology of gout, the known mechanism of action of these drugs, the proven effectiveness of these medications in other painful or inflammatory conditions, and evidence of equivalence in head-to-head trials of patients with acute gout. We judged the evidence for use of corticotropin to be of moderate strength because of high risk of bias in the only 2 head-to-head randomized trials.
Pharmacologic Management of Hyperuricemia in Patients With Gout
We found 11 systematic reviews (37-47), 1 metaanalysis (48) (92) , and the open-label EXCEL (Febuxostat/ Allopurinol Comparative Extension Long-Term) study (93) . The details of these studies are presented in Table  2 . More than 90% of enrolled participants were men; mean age was approximately 52 years, and mean baseline serum urate level was approximately 583 μmol/L (9.8 mg/dL).
Across the studies, patients were randomly assigned to various doses of febuxostat (40, 80, 120 , and/or 240 mg/d; doses >80 mg/d are not FDAapproved), allopurinol, or placebo, with adjustment for renal insufficiency. Patients in all studies received prophylaxis with colchicine or naproxen when starting urate-lowering therapy. The findings were as follows. First, all active therapies decreased serum urate levels compared with placebo. Second, no important differences were seen between treatment groups or between active treatment and placebo in the frequency of acute gout attacks. Third, in the long-term extension study (EXCEL), patients achieving a serum urate level less than 357 μmol/L (<6 mg/dL) had progressive decreases in their risk for acute gout attacks (to about 5% at 12 months and near zero at 32 months), regardless of choice of urate-lowering therapy. Fourth, febuxostat, 80 mg/d, was more effective than allopurinol, 300 mg/d, at decreasing serum urate levels. Fifth, no major or important differences were seen in outcomes or total adverse events between allopurinol, 300 mg/d, and febuxostat, 40 mg/d. Sixth, discontinuation of colchicine or naproxen prophylaxis after 8 weeks in both APEX and FACT was associated with a spike in acute gout attacks not seen in CONFIRMS, which maintained prophylaxis throughout the 6-month duration of the study. Finally, studies assessing comparative effectiveness in subgroups were sparse but generally found no differences in clinical outcomes, although they had limited power to detect such differences (3). Several smaller studies had findings similar to those of the larger randomized, controlled trials (49, 55, 63, 94, 95) .
Appendix Table 3 (available at www.annals.org) presents selected adverse events seen in the randomized, controlled trials of urate-lowering therapy. Differences between active treatments and between active treatments and placebo were mostly small and not statistically significant. Although skin rash was not statistically significantly more likely in allopurinol-treated patients in these trials, observational evidence suggested that allopurinol is a cause of DRESS (drug rash with eosinophilia and systemic symptoms) syndrome (65, 68 -70, 72) and is more common in patients with the HLA-B*5801 allele (41, 62, 66, 74, 79, 86, 88) .
In summary, high-strength evidence suggests that urate-lowering therapy reduces serum urate levels. However, it does not reduce the risk for acute gout Continued on following page attacks in the first 6 months. Long-term extension studies show that patients continuing urate-lowering therapy who achieve serum urate reductions have fewer acute gout attacks, which supports the moderatestrength conclusion that urate-lowering therapy reduces the risk for such attacks after about 1 year.
Prophylaxis Against Acute Gout Attacks at Initiation of Urate-Lowering Therapy
Initiation of therapy to decrease serum urate levels is associated with an increased frequency of acute gout attacks (96) . This is a likely explanation for the observation that use of urate-lowering therapy does not reduce the frequency of acute gout attacks compared with placebo for the first 6 months. More than 30 years ago, investigators tested colchicine as prophylaxis against acute attacks for patients starting uricosuric therapy (97, 98) . However, the first randomized, placebocontrolled trial of colchicine prophylaxis at initiation of allopurinol therapy was not published until 2004 (57) . In this study, investigators randomly assigned 51 patients to colchicine, 0.6 mg twice daily, or placebo when starting allopurinol therapy at 100 mg once daily and titrating upward, with a target serum urate level of 387 μmol/L (6.5 mg/dL). Occurrence of gout attacks was recorded by patient recall at 3-and 6-month visits. Among 43 patients who completed the trial (mean age, 63 years; >50% male; >60% with tophi; approximately 10% with chronic renal insufficiency), 77% of placebo recipients versus 33% of colchicine-treated patients had gout attacks (P = 0.008). During the first 3 months of treatment, placebo recipients averaged about 2 attacks and colchicine-treated patients averaged about 0.5 attack. From months 3 to 6, this advantage diminished, with about 1 attack per patient in the placebo group and almost no attacks in the colchicine group. Diarrhea was much more common in colchicine-treated patients (43%) than in placebo recipients (approximately 4%).
The use of prophylactic therapy concomitant with the initiation of urate-lowering therapy has been the recommended standard of care for many years (99, 100). All 3 of the recent large trials of urate-lowering therapy (FACT, APEX, and CONFIRMS) used prophylaxis with colchicine or NSAIDs (90 -92), even though no randomized trials had assessed NSAIDs as a prophylactic therapy for urate-lowering therapy. In both FACT and APEX, the number of acute attacks spiked after discontinuation of prophylaxis at 8 weeks, with an approximate doubling of the proportion of patients reporting an attack (from 20% before to 40% after discontinuation). CONFIRMS, which continued prophylaxis for the entire 6 months of the trial, saw no spike in attacks.
One randomized trial with high risk of bias compared different durations of colchicine prophylaxis in patients with gout initiating allopurinol therapy (59) . However, the outcome measure was "any evidence of recurrence of gouty arthritis," and the criteria for this clinical event and loss to follow-up were not specified.
Wortmann and colleagues collected adverse event data from all 3 of the major trials of febuxostat and allopurinol and pooled data from FACT and APEX (56) . None of these trials randomly assigned patients to different prophylaxis regimens; rather, selection bias was potentially present because assignment was at the discretion of the treating physician. In all 3 studies, upper respiratory infection was the most frequently reported adverse event (8% to 9% in each group, with no statistically significant difference). Overall, adverse events were higher with colchicine prophylaxis than with naproxen prophylaxis (55% vs. 44%). Diarrhea was about 3 times more common with colchicine than with naproxen (8.4% vs. 2.7%). In CONFIRMS, no statistically significant difference was seen in overall adverse events reported (about 55% in both groups), but gastrointestinal and abdominal pains were about 3 times more frequent in naproxen-treated patients (3.2% vs. 1.2%). Headache was more commonly reported in colchicine-treated patients (2.8% vs. 0.9%).
In summary, high-strength evidence suggests that prophylaxis with either colchicine or NSAIDs reduces the risk for acute gout attacks in patients initiating urate-lowering therapy. The optimal duration of such prophylactic therapy is unknown, but moderatestrength evidence suggests that it should be longer than 8 weeks.
Treatment Monitoring of Patients With Gout
A large body of evidence (which includes the fact that urate is soluble up to a concentration of about 404 μmol/L [6.8 mg/dL], above which precipitation may begin [101]) supports the hypothesis that lower serum urate levels are causally associated with a lower rate of acute gout attacks. A post hoc analysis that combined data from 3 large trials (ULT, FACT, and APEX) provided the best clinical data about the relationship between achieved urate levels and risk for acute gout attacks (102) . That analysis included more than 1800 patients with gout and a baseline serum urate level of 476 μmol/L (8.0 mg/dL) or greater. The achieved urate level was 1 of 3 variables (along with baseline presence of tophi and percentage change in serum urate level from baseline) that were associated with acute gout attacks requiring treatment (adjusted odds ratio, Patients who achieved a serum urate level less than 357 μmol/L (<6.0 mg/dL) at the end of 1 year had a risk for acute gout attacks of approximately 5%, whereas patients with levels at or above 357 μmol/L (≥6.0 mg/dL) had risks of about 10% to 15%. Other reports, including analyses from several retrospective cohort studies, support a relationship between achieved lower serum urate levels and reduced risk for acute gout attacks (103-108). One study that reported outcomes for a cohort of 158 patients with incident gout who were followed for a mean of 13 years found that 70% had a flare during the extended follow-up and that higher urate levels were predictive of a subsequent acute flare (odds ratio, 1.35 [CI, 1.2 to 1.5]) (109) .
There are potential nonarticular impacts of hyperuricemia in patients with gout that may be affected by serum urate levels. One retrospective observational study of U.S. veterans with gout used the U.S. Department of Veterans Affairs data warehouse to follow 2116 patients for a mean of 6.5 years. Comparing patients with high versus low serum urate levels, the investigators reported about a 2-fold difference in new diagnoses of kidney disease (4% vs. 2% at year 1 and 9% vs. 5% at year 3, respectively) (110) . A second study used U.S. claims data to identify 24 108 pairs of patients with gout who were or were not treated with urate-lowering therapy and were followed for slightly more than a year. Cardiovascular events were common in both groups (incidence rates were 24% and 21%), but there were no statistically significant differences in the composite outcome or its components between groups (111).
In summary, the only way to assess whether uratelowering therapy in patients with gout is having the desired effect on serum urate levels is by monitoring, but no direct evidence supports or refutes the value of such monitoring. The notion that decreasing serum urate levels will reduce the risk for acute gout attacks is supported by physiology and observational evidence. The evidence base for use of serum urate level as a target value for treatment is limited by the lack of any trial that has based treatment decisions on different specific targets (such as a target of 416 vs. 357 μmol/L [7.0 vs. 6.0 mg/dL]) or any target as opposed to treating symptoms. Treating to a target necessarily means increasing doses of medication in patients who may be asymptomatic. The value of such a strategy has yet to be proved, and examples exist from other studies using intermediary biomarkers (such as elevated blood pressure or blood glucose level or low hemoglobin level), in which treating to a target resulted in more adverse effects than benefits. Thus, despite the strong biologic appeal of such a strategy and its advocacy by major specialty society guidelines (99, 100, 112) , we judged the strength of evidence for monitoring to be low.
Discontinuation of Pharmaceutical Management for Patients Receiving Medications for Chronic Gout
Three prospective observational cohort studies found that some patients who were currently being treated remained asymptomatic for up to 2 or 3 years after urate-lowering therapy was stopped and that serum urate levels in the presence or absence of treatment were strong predictors of which patients remained asymptomatic (113) (114) (115) . Because a strategy of treatment discontinuation has never been tested in a clinical trial, we judged the strength of evidence to be insufficient that criteria exist to identify patients for whom urate-lowering therapy can be safely discontinued.
DISCUSSION
A principal finding of this review is that highstrength evidence suggests that colchicine, NSAIDs, and corticosteroids help reduce symptoms in patients with acute gout (Table 3) . Despite the limited number of placebo-controlled trials, we were able to reach strong conclusions due to specific features of gout, namely that symptoms result from an inflammatory reaction to the deposition of urate crystals, which occurs when the level of urate increases above its saturation point in the blood. Hence, in an era that predated the widespread practice of placebo-controlled trial testing of therapies, clinicians prescribed anti-inflammatory medications to treat symptoms of acute gout.
Corticosteroids are among the most powerful and effective anti-inflammatory medications available. Although no randomized, placebo-controlled trials have tested their use in acute gout, corticosteroids have proven efficacy in other inflammatory conditions, which increases our confidence that they are effective in treating the inflammatory reaction in acute gout. With regard to the management of hyperuricemia in patients with gout, we likewise used direct and indirect evidence to reach conclusions about the effectiveness of urate-lowering therapy at reducing the risk for acute gout attacks over time, despite the fact that this outcome has not been studied in any placebo-controlled trial lasting longer than a few months ( Table 3) . We based our rating of moderate strength of evidence on the high-strength evidence that urate-lowering therapy reduces serum urate levels, that serum urate level is a strong predictor of risk for acute gout attacks, and that the open-label extension studies of urate-lowering therapy trials have shown a graded relationship between the serum urate level achieved and the risk for acute gout attacks. We concluded that after the initial period of increased risk for acute gout attacks associ- 
REVIEW
Systematic Review in Support of ACP Guideline on Management of Gout ated with initiation of urate-lowering therapy, such therapy reduces the risk for acute attacks. The increased risk during the initial period can be reduced with concurrent use of anti-inflammatory prophylaxis. Our review reached stronger strength-of-evidence ratings than some prior reviews, particularly Cochrane reviews, that concluded that the strength of evidence is "inconclusive" with regard to corticosteroids (116) , "low-quality" with regard to colchicine (117), "limited" with regard to NSAIDs (118), and "low-moderate" with regard to allopurinol (44) . Non-Cochrane reviews tended to reach stronger conclusions (for example, "all therapies were found to be effective" [119] ).
The most important question to be answered for the treatment of gout in primary care is whether using urate-lowering therapy to treat all patients to a specific goal, such as less than 357 μmol/L (<6.0 mg/dL), improves patient outcomes. This concept of "treat-totarget" is supported by indirect evidence but has not been tested. Guidelines and recommendations about treatment target thresholds vary; for example, less than 357 μmol/L (<6.0 mg/dL) is the most commonly suggested threshold, but recent American College of Rheumatology guidelines suggest a threshold of less than 297 μmol/L (<5.0 mg/dL) for some patients "to improve signs and symptoms of gout" (100). However, for many patients whose gout is clinically wellcontrolled (no flares) during urate-lowering therapy, no direct data support such targets. In fact, the results of one cohort study suggest that once gout has been asymptomatic for 5 years, urate-lowering therapy might be discontinued for many years as long as serum urate levels remain acceptable (for example, <416 μmol/L [<7 mg/dL]) (114).
Our review identified several limitations beyond the lack of placebo-controlled studies. For many of the questions of interest, data were not reported on the subgroups or outcomes of interest. Only 10 studies explicitly stated that patients came exclusively from primary care sites or included such patients. We thus judged this evidence to be moderately applicable to primary care.
In summary, use of colchicine, NSAIDs, and corticosteroids to relieve symptoms of acute gout attacks is supported by high-strength evidence. In addition, highstrength evidence suggests that urate-lowering therapy with allopurinol or febuxostat decreases serum urate levels, and moderate-strength evidence shows that it reduces the risk for acute gout attacks after several months. In patients initiating urate-lowering therapy, high-strength evidence supports use of prophylactic colchicine or NSAIDs for more than 8 weeks to reduce the risk for acute gout attacks. Use of a treat-to-target strategy for patients with gout and hyperuricemia has logical appeal and is supported by observational evidence but has not been experimentally tested. A longterm trial of a treat-to-target strategy is the most important research need for the management of gout in primary care.
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